2026-05313Notice

FDA Extends Reproductive Drugs Advisory Panel

Published Date: 3/18/2026

Notice

Summary

The FDA is renewing its Obstetrics, Reproductive and Urologic Drugs Advisory Committee for two more years, keeping it active until March 23, 2028. This committee helps make sure medicines related to pregnancy, reproductive health, and urology are safe and effective. Doctors, patients, and drug makers all benefit from this continued expert advice, with no new costs or changes in how the committee works.

No Economic Impacts Identified for this Document

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
3/18/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register